NASDAQ | ETF
The fund uses a "passive management" approach to track the performance, before fees and expenses, of the index.
The index is constructed using a rules-based methodology that identifies companies in the pharmaceutical and/or biotechnology industries with publicly traded ordinary shares listed on major stock exchanges in developed markets, as classified by BITA GmbH.
Under normal circumstances, the fund will invest at least 80% of the fund"s net assets in component securities that make up the index.
The fund is non-diversified.
Top 20 Holdings
| Asset | Name | Sector | Industry | Weight |
|---|---|---|---|---|
| LLY | Eli Lilly and Company | Healthcare | Drug Manufacturers - General | 15.71% |
| JNJ | Johnson & Johnson | Healthcare | Drug Manufacturers - General | 9.23% |
| ABBV | AbbVie Inc | Healthcare | Drug Manufacturers - General | 7.24% |
| ROG | Roche Holding AG | Healthcare | Drug Manufacturers - General | 5.18% |
| AZN | AstraZeneca PLC | Healthcare | Drug Manufacturers - General | 4.95% |
| NOVN | Novartis AG | Healthcare | Drug Manufacturers - General | 4.91% |
| MRK | Merck & Company Inc | Healthcare | Drug Manufacturers - General | 4.64% |
| AMGN | Amgen Inc | Healthcare | Drug Manufacturers - General | 4.11% |
| GILD | Gilead Sciences Inc | Healthcare | Drug Manufacturers - General | 3.79% |
| 0QIU | Novo Nordisk A/S Class B | 3.64% | ||
| PFE | Pfizer Inc | Healthcare | Drug Manufacturers - General | 3.57% |
| SAN | Sanofi SA | Healthcare | Drug Manufacturers - General | 2.74% |
| VRTX | Vertex Pharmaceuticals Inc | Healthcare | Biotechnology | 2.70% |
| BMY | Bristol-Myers Squibb Company | Healthcare | Drug Manufacturers - General | 2.59% |
| GSK | GlaxoSmithKline PLC | Healthcare | Drug Manufacturers - General | 2.39% |
| REGN | Regeneron Pharmaceuticals Inc | Healthcare | Biotechnology | 1.81% |
| CSL | CSL Ltd | Healthcare | Biotechnology | 1.45% |
| ZTS | Zoetis Inc | Healthcare | Drug Manufacturers - Specialty & Generic | 1.28% |
| ARGX | Argen-X | Healthcare | Biotechnology | 1.26% |
| ALNY | Alnylam Pharmaceuticals Inc | Healthcare | Biotechnology | 1.25% |